Safety and Efficacy Evaluation of CD19-UCART

NASuspendedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

December 15, 2023

Study Completion Date

December 30, 2023

Conditions
Acute Lymphoblastic Leukemia (ALL)Non Hodgkin Lymphoma (NHL)
Interventions
BIOLOGICAL

CD19-UCART

A conditioning therapy with cyclophosphamide and fludarabine will be conducted before CD19-UCART injection. VP16 can be added to the conditioning therapy.

Trial Locations (2)

310003

First Affliated Hospital of Zhejiang University, Hangzhou

450052

First Affliated Hospital of Zhengzhou University, Zhengzhou

Sponsors
All Listed Sponsors
collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

collaborator

First Affiliated Hospital of Zhejiang University

OTHER

collaborator

Second Xiangya Hospital of Central South University

OTHER

lead

Bioray Laboratories

INDUSTRY

NCT03229876 - Safety and Efficacy Evaluation of CD19-UCART | Biotech Hunter | Biotech Hunter